



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



Analysis of an intronic promoter within *Synj2*

Antonio Planchart

Department of Biological Sciences, North Carolina State University, Campus Box 7617, Raleigh, NC 27695, USA



ARTICLE INFO

Article history:

Received 17 September 2013

Available online 5 October 2013

Keywords:

Synaptojanin

Inositol polyphosphate phosphatase

Spermatogenesis

Non-canonical promoter

Mouse

ABSTRACT

Synj2 (synaptojanin 2) encodes an inositol polyphosphate phosphatase that functions in recycling neurotransmitter vesicles and is implicated in spermatogenesis. Transcription of *Synj2* is thought to occur from one of two promoters based on analysis of a variable 5' untranslated region. Clustering all known mouse *Synj2* transcripts led us to uncover a novel subset of transcripts that appears to derive from a region located within intron 7. We identified two alternate splice variants emanating from use of this promoter. These alternate splice variants manifest developmental stage specificity and somatic versus gametic differences in expression.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Synaptojanins belong to a family of inositol polyphosphate phosphatases characterized by the presence of an N-terminal phosphatidylinositol polyphosphate 3' and 4' phosphatase domain similar to the yeast Sac1 domain and a central inositol polyphosphate 5' phosphatase (IPP5Pase) domain [1,2]. Mammals possess two paralogs, *Synj1* and *Synj2*, encoding proteins that are approximately 55% identical over their Sac1-like and IPP5Pase domains but with divergent carboxyl termini [3,4].

Synj1 was identified in rat as p145, a Grb2-binding brain protein enriched in presynaptic nerve terminals and also present in cultures of neuronal but not glial cells [5]. It accounts for the majority of phosphatidylinositol 5-phosphatase activity in adult rat brain lysates [6]. *Synj1* functions in clathrin-mediated endocytosis via interactions with dynamin 1 [5], amphiphysin [7], endophilin [8,9] and syndapin [10]. *Synj1* knockout mice die perinatally and exhibit neurological defects including increased neuronal levels of phosphatidylinositol-4,5-bisphosphate and an accumulation of presynaptic clathrin-coated secretory vesicles. *Synj2* knockout mice have not been reported. However, *in vitro* small interfering RNA experiments implicate human *Synj2* in clathrin-coated receptor internalization and coated vesicle formation, both of which are drastically diminished in its absence [11]. Interestingly, overexpressing *Synj2* rescues these defects, whereas overexpressing *Synj1* does not [11], suggesting that the paralogs have different functions in receptor-mediated endocytosis.

In contrast to *Synj1*, rat *Synj2* is ubiquitously expressed, albeit more so in brain and testis than in other tissues [3]. *Synj2* undergoes extensive alternative splicing, mostly within the 3' region.

In mice, 7 splice variants (α – ζ) are reported [12,13], whereas rats have three major splice variants (A, B1 and B2) [4]. In rats, these variants encode proteins with marked differences in subcellular localization and protein–protein interactions. For example, *Synj2A* (but not B1 or B2) is recruited to mitochondria by association with outer mitochondrial protein 25 where it functions in intracellular distribution of the organelle [14], whereas *Synj2B1/B2* localize to the sperm manchette [4]. The manchette is a transient microtubule-derived structure implicated in nuclear elongation and chromatin organization during sperm maturation [15] and consistent with a role in spermatogenesis, our laboratory discovered multiple non-synonymous substitutions in the *t* haplotype allele of mouse *Synj2* and linked these mutations with the phenomenon of *t* haplotype-specific male sterility [16]. Lastly, constitutive activation of Rac1, a small GTPase, causes translocation of human *Synj2* from the cytoplasm to the plasma membrane via the C-terminus of *Synj2* resulting in inhibition of receptor-mediated endocytosis [4,17].

In mouse, transcription of *Synj2* occurs from one of two promoters. The resulting transcripts differ in their 5' untranslated region (UTR) but translation is initiated from the same start codon [12]. The potential for a third, downstream promoter was suggested by the identification of a novel transcript in the RIKEN collection [18] with a 5' UTR mapping within the 3' end of intron 7. A more comprehensive clustering of all known *Synj2* transcripts onto the genomic locus identified a small subset of transcripts that originate within this intron. The resulting transcripts, including the RIKEN transcript AK019694, truncate most of the Sac1 homology domain yet leave intact the catalytic site encoded by this domain. In this report, we describe the promoter activity resident in intron 7. In addition, we demonstrate stage-specific and somatic versus gametic alternate splicing within the 5' UTR derived from use of

E-mail address: ajplanch@ncsu.edu

this promoter in the developing mouse testis. Our analysis identifies a novel promoter that does not conform to known canonical promoter sequences and may define a new class of RNA polymerase II promoter.

2. Materials and methods

2.1. Mice

All experiments were conducted using B6SJL F1 male mice obtained from The Jackson Laboratory (Bar Harbor, ME). The day of birth was designated as postpartum day (dpp) 0. Mice were maintained under normal conditions. All procedures were approved by the Animal Care and Use Committee.

2.2. Northern analysis and probe synthesis

A multiple tissue Northern blot of Balb/c-derived polyA mRNA (Clontech) was probed following the manufacturer's protocol. The probe consisted of a 623 bp fragment containing 273 bp of intron 7, all of exons 8 and 9 and part of exon 10 (NM_011523) radiolabeled using RediPrime II (GE Healthcare) as per manufacturer's protocol. Washes were performed at 60 °C in increasingly stringent solutions of SSC supplemented with 0.5% v/v SDS. Probe signal was detected by autoradiography.

2.3. RNA extraction and reverse transcription

Total RNA was extracted with TRIzol (Invitrogen) according to the manufacturer's protocol. RNA quality was assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies). First-strand cDNA was synthesized from 2 µg of total RNA using MMLV reverse transcriptase (RT) from a RETROscript kit (Ambion) according to the manufacturer's protocol. Negative controls were included.

2.4. Polymerase chain reaction (PCR) and primer extension

Standard PCR conditions were used (95 °C for one minute followed by 30 cycles of 95 °C for 30 s, 55 °C for 30 s, 72 °C for 30 s). Taq polymerase, buffer and dNTPs were purchased from Eppendorf. First-strand cDNA for primer extension was synthesized from total RNA primed with an exon 10-specific primer. 5' rapid amplification of cDNA ends (RACE) was performed with the SMART RACE kit (Clontech) following the recommended protocol using a nested *Synj2* exon 10-specific primer and the anchor primer provided with the kit.

2.5. Protein extraction

All procedures were performed on ice except where noted. Mouse brain, liver and testis tissues from a wild-type male were harvested immediately after euthanasia, minced in chilled buffer AB (25 mM Tris pH 7.9, 12.5% glycerol, 2.5 mM MgCl₂, 0.1 mM EDTA, 12 mM KCl, 10 mM 2-mercaptoethanol supplemented with protease inhibitor cocktail (SIGMA)) and homogenized using a rotor-stator. Prior to high-speed centrifugation to obtain the cytoplasmic fraction, polyethylenimine (PEI) was added to the homogenate in order to precipitate nucleic acid and nucleic acid-binding proteins. Cytoplasmic protein was isolated by centrifugation at 100,000×g for 1 h at 4 °C (S100). The pellet was resuspended in chilled buffer C (50 mM Tris pH 7.9, 12.5% glycerol, 0.1 mM EDTA, 25 mM KCl, 10 mM 2-ME supplemented with protease inhibitor cocktail) and rocked at 4 °C for 30 min in order to extract soluble proteins precipitated by PEI. The PEI-insoluble fraction was separated from the particulate fraction by

centrifugation at 100,000×g for 1 h at 4 °C (PEI100). The remaining pellet was extracted with 1.5% v/v Triton X-100 in buffer C overnight at 4 °C followed by centrifugation at 100,000×g for 1 h at 4 °C (P100). The S100, PEI100 and P100 fractions were flash-frozen in liquid N₂ and stored at –80 °C until needed.

2.6. SDS-PAGE and Western blotting

Proteins were resolved on 8.5% SDS-PAGE as previously described [19]. Electroblothing was performed as previously described [20] with the following modifications: proteins were blotted onto Immobilon-P (Millipore) in a transfer solution consisting of 15.6 mM Tris pH 8.2, 120 mM glycine, 20% v/v methanol and 0.1% v/v SDS. Analysis of *Synj2* expression was performed with anti-*Synj2* antibody (1:500 dilution; gift from P. De Camilli) recognizing a C-terminal epitope (amino acid 1255–1391) of rat *Synj2* [4] followed by detection using an alkaline phosphatase-conjugated secondary antibody supplemented with NBT and BCIP (SIGMA).

2.7. Cell culture and luciferase assay

All assays were performed using NIH-3T3 cells grown in disposable 16-well tissue-culture trays (Costar) to approximately 75–80% confluency. Cells were grown in enriched DMEM supplemented with 10% calf serum (Gibco) at 37 °C in 5% CO₂. Candidate promoter fragments from intron 7 were PCR amplified and subcloned into pCR2.1 using the TOPO-TA kit (Invitrogen) per manufacturer's instructions. Promoter fragments were removed by digesting with *Xho*I and *Hind*III and cloned into *Xho*I/*Hind*III-linearized pGL3-Basic (Promega). Each fragment was cloned into pGL3-Basic in both orientations. Six constructs were tested: 213 (+), 213 (–), 278 (+), 278 (–), 365 (+) and 365 (–). Stoichiometrically equal amounts of each construct were transfected in triplicate using Lipofectamine (Invitrogen) per manufacturer's protocol. Cells were cultured for 24 h followed by lysis in luciferase reagent (Bright-Glo; Promega). Luciferase activity was measured in an HT Synergy plate reader (Bio-Tek) with a gain setting of 200. Data were analyzed in Excel (Microsoft Corp.).

3. Results

3.1. Truncated *Synj2* transcripts map to intron 7

Synj2 transcripts derive from one of two promoters based on the finding of two distinct 5' UTRs in full-length transcripts [12]. While attempting to estimate the relative preference for these promoters based on the number of times each 5' UTR recurs in the EST dataset at NCBI, we identified three out of 204 variants (UniGene Mm.236068, UGID: 324106) that have 5' UTRs mapping to intron 7. Of these, transcript AK019694 [18] had the longest 5' UTR whereas transcripts AK161467 and AY823997 were shorter variants of AK019694 (Supplemental Fig. 1). We interpreted this to mean that intron 7 harbors a promoter.

To determine if these transcripts originate from a promoter within intron 7, we performed RT-PCR with primers specific to the 5' UTR of AK019694. Whereas primers designed to the 5' most region of AK019694 consistently failed to amplify a product, primers designed to more distal regions of the 5' UTR produced an amplicon (Fig. 1A). Next, we isolated an ~530 bp fragment by 5' RACE (Fig. 1B). Based on sequence analysis, the 5' end of this transcript maps within intron 7 at nucleotide 2181 (the length of intron 7 is 2518 bp). We refer to this transcript as *Synj2*^{DSac1}.




Fig. 1. 5' UTR mapping analysis. (A) Staggered primers to the 5' UTR of AK019694 were used in combination with an exon 10 primer to amplify cDNA transcripts derived from poly dT-primed reverse transcription reactions. Primers within the first 30 nucleotides of AK019694 consistently failed (lane 2 and right diagram) whereas internal primers produced an amplicon of the expected size (lane 1 and left diagram). (B) 5' RACE produced a ~530 bp product (lane 1) whose 5' end mapped to intron 7. Larger fragments were observed, corresponding to transcripts most likely derived from the far-upstream promoters. Lane 2 is the human transferrin receptor positive control.

3.2. Tissue-specific *Synj2* expression

Rat *Synj2* is expressed in several adult tissues, with the exception of liver [3]. In testis, the two most prominent transcripts are 5.2 and 3.5 kb and, to a much lesser extent, a 7.5 kb transcript that is prevalent in other tissues is faintly observed [3]. To determine transcript sizes and tissue expression profiles and to identify alternate splice variants of mouse *Synj2*, we probed a multiple tissue Northern blot (Clontech). The probe consisted of a fragment conserved in all reported alternate splice variants, with the exception that it included the 3'-most 273 bp of intron 7. In contrast to rat [3], *Synj2* expression was observed in all tissues, including liver, except for skeletal muscle (Supplemental Fig. 2). A 1.7 kb transcript occurred most frequently although alternatively spliced variants were observed in heart and testis, and to a lesser extent in brain and liver. In testis, four transcript sizes were observed, corresponding to 0.9, 1.7, 3.3 and 3.8 kb, whereas significantly larger transcript variants (≤ 7.5 kb) were observed in heart and brain.

3.3. *Synj2* partitions into soluble and particulate fractions

Prior studies provided evidence that rat *Synj2* partitions into the particulate fraction [3] whereas others have shown that human *SYNJ2* cycles between the cytoplasm and plasma membrane via interaction with Rac1 [17]. In order to determine the partitioning properties of mouse *Synj2*, we fractionated proteins into cytoplasmic and membrane-bound fractions. In addition, because *Synj2* contains an RNA-binding motif (RP1; IPR000504), we co-precipitated nuclear components with the membrane fraction by addition of polyethylenimine, a positively charged polyelectrolyte that precipitates nucleic acids and nucleic acid-binding proteins [21]. Thereafter, we investigated the partitioning of *Synj2* into cytoplasmic, nuclear or particulate fractions by Western blot analysis using an antibody to a carboxyl terminus 137 amino acid epitope of rat *Synj2B* [4]. Two isoforms of *Synj2* were observed in brain: one with a molecular mass of 160 kDa in the S100 and PEI100 fractions, and a doublet centered at approximately 116 kDa in the pellet fraction (Fig. 2). The 116-kDa isoform corresponds to the predicted size encoded by *Synj2^{DSac1}*. *Synj2* was not detected in either testis or liver (data not shown) even though transcription is observed by Northern blot (Supplemental Fig. 2). The most plausible explanation is that the epitope detected by the antibody is absent from the testis variant of mouse *Synj2* because exons encoding the epitope are targets of alternative splicing.




Fig. 2. Western analysis of soluble and particulate fractions from brain lysates. The soluble and PEI-precipitated isoforms of *Synj2* are indistinguishable (S, P1) whereas the membrane-associated isoform (P2) migrates at ~120 kDa as a doublet. A model representing the two isoforms is shown to the right.

3.4. Differential expression of *Synj2* in somatic versus gametic cells

Synj2 is thought to be required during spermatogenesis or for normal sperm function [4,16]. The mitotic phase of mouse spermatogenesis begins at ~7dpp. Dividing spermatogonia transition into meiosis at ~11dpp and spermatids are observed by ~21.5dpp whereas mice are reproductively mature at ~35dpp. During these stages, changes in the number and architecture of the somatic cells (Sertoli cells) that nourish the developing sperm are also occurring. To assess expression of *Synj2^{DSac1}* during spermatogenesis, we performed RT-PCR on 7dpp (mitosis), 14dpp (zygotene), 18dpp (pachytene), 21dpp (meiosis II), 28dpp (post-meiotic spermatid), 35dpp (maturation) and adult testis-derived mRNA. We also assayed expression of *Synj2^{DSac1}* in Sertoli cells derived from spermatogonia-depleted adult *Kit^{w/wv}* mice [22]. As shown in Fig. 3, *Synj2^{DSac1}* is expressed at the earliest stage (7dpp). At 14dpp, a smaller amplicon coamplifies to a lesser extent with the larger amplicon seen exclusively at 7dpp and by 21dpp becomes the prominent transcript. In the testis of wild type mice, only the smaller amplicon is expressed at 28 and 35dpp, and in adults; whereas in *Kit^{w/wv}* testes, which are spermatogonia depleted, only the larger amplicon is expressed. The simplest interpretation of this result is that this variant of *Synj2^{DSac1}* is somatic cell-specific whereas the smaller variant is germ cell-specific. The difference between the two variants is due to alternative splicing of the intron 7-derived 5' UTR.

3.5. Promoter activity resides within intron 7

We tested the promoter activity of various intron 7 fragments. First, we cloned a 365 bp fragment of intron 7, beginning at




Fig. 3. Developmental and cell-type differential expression of *Synj2^{DSac1}*. Testis at different stages of development were assayed for *Synj2^{DSac1}* expression. A switch in alternate transcripts is seen at ~21 dpp. The larger transcript is somatic cell-specific whereas the smaller transcript appears to be germ cell-specific.

nucleotide 2154 and extending to the junction with exon 8, into pGL3-Basic (Promega) in both orientations. Successively smaller fragments (273 and 213 bp) were also cloned in in both orientations. In all, 8 constructs were tested – 2 for each of the 3 promoter fragments in the plus and minus orientations, the empty vector (pGL3-Basic) and a positive-control (pGL3-Control). All constructs were transfected in stoichiometrically equal amounts by lipofection into NIH-3T3 cells in triplicate. After 24 h, the cells were lysed in luciferase assay solution and luminosity measured for each construct. As seen in Fig. 4, the larger construct (365 bp) expressed luciferase at a level approximately 20 percent of the constitutively active control, pGL3-Control. Approximately 3–4-fold less activity was observed from the smaller constructs (273 and 213 bp). Importantly, luciferase activity was observed only for the promoter fragments in the plus orientation whereas luminosity from the minus orientation did not differ from the empty vector control. Computational analysis of the 365 bp promoter fragment failed to identify canonical promoter sequences although several transcription factor binding sites were identified (Table 1 and Supplemental Fig. 3), including GC-box binding sites for SP1 and members of the Zfx and Zfy transcription factor family implicated in mammalian sex determination. These results demonstrate that intron 7 harbors a promoter.




Fig. 4. Luciferase assay. Three overlapping fragments (365, 273 and 213 bp) of intron 7 were cloned separately into a luciferase reporter construct and transfected into NIH-3T3 cells. Luminosity was measured and compared to a control luciferase (C) driven by an SV40 promoter. All assays were performed in triplicate and error bars are SD. Asterisks indicate significance (* $p \leq 0.05$; ** $p \leq 0.01$).

3.6. *Synj2^{DSac1}* encodes a truncated isoform of the full-length protein

We analyzed the 5' sequence of *Synj2^{DSac1}* to identify the putative translation start site and determined that the first in-frame start codon is located at nucleotide 40 of exon 8 (Supplemental Fig. 3). The predicted AUG, surrounded by an imperfect Kozak consensus sequence (ACCUAUGA) [23], is in-frame with the remaining *Synj2* coding sequence and predicts an ~120-kDa protein consistent with the size observed by Western analysis (Fig. 2). This newly predicted N-terminus is 54 amino acid residues upstream of the catalytic site of the Sac1 homology domain [1].

4. Discussion

We demonstrate the feasibility of a straightforward strategy designed on the premise that clustering EST and mRNA sequences onto the genomic locus of origin can identify novel promoters. It is accepted that enhancer and repressor elements are frequently found within introns. Alternative or cryptic promoters are often located in the first or second intron of a gene and when used in place of the upstream promoter, produce variation in the amino terminus or result in novel 5' UTRs. The previously identified transcription start sites in *Synj2* illustrate the latter case [12]. However, promoters located in distal introns that produce mRNA transcripts encoding truncated isoforms of full-length proteins are not as common, but occur [24–27]. Use of these promoters might lead to novel ways of controlling protein function. For example, they may affect allosteric control by the omission of regulatory domains, or change substrate specificity in the case of enzymes; modify protein complex formation by disrupting protein–protein interactions; or alter the spatial activity of the protein by changes in subcellular targeting.

We have shown that the fragment of intron 7 of *Synj2* harbors a promoter located >65 kb downstream of the canonical promoter. Computational analysis did not identify hallmark eukaryotic promoter sequences, such as TATA box or Inr [28], although a number of transcription factor binding sites were strongly predicted, including sites for GC-box binding proteins, NfκB and Smad. The significance of these sites remains unknown. The promoter is moderately active relative to a constitutively active, strong promoter such as SV40.

Synj2 is a member of a rare class of enzymes having distinct but related catalytic activities located within separate domains. The N-terminal domain is a Sac1 homology domain homologous to the yeast Sac1p protein [29]. It encodes a phosphatidylinositol polyphosphate phosphatase that converts phosphatidylinositol-3-phosphate (PI3P), PI4P and PI4,5P₂ to PI [1]. The catalytic site of this domain belongs to a family of phosphatases that includes the *Yersinia pestis* tyrosine phosphatase

Table 1

Distribution of transcription factor binding sites in the Intron 7 promoter.

Factor name	Anchor ^a	Strand ^b
Calsenilin, presenilin binding protein, EF hand transcription factor	241	+
Cellular and viral Myb-like transcriptional regulators	7	–
E-box binding factors	26	+
EGR/nerve growth factor induced protein C & related factors	191, 193	–
EV11-myleoid transforming protein	348	–
GC-Box factors SP1/GC	188, 194, 323	–
Human and murine ETS1 factors	310, 348	+/-
Krueppel like transcription factors	190, 192, 194, 231	–
Myc associated zinc fingers	193	–
Myeloid zinc finger 1 factors	195	–
Myoblast determining factors	35, 36	+/-
MYT1 C2HC zinc finger protein	314	–
NeuroD, Beta2, HLH domain	154	+
Nuclear factor kappa B/c-rel	94, 95	+/-
Pur- α	190	–
RXR heterodimer binding sites	58, 244	-/+
v-ERB and RAR-related orphan receptor alpha	239	+
Vertebrate homologues of enhancer of split complex	27	+
Vertebrate SMAD family of transcription factors	204, 209, 334	+/-/+
Zfx and Zfy-transcription factors implicated in mammalian sex determination	248	–
Zinc binding protein factors	190, 193	+

MatInspector software from Genomatix (www.genomatix.de) was used to analyze the 365 bp promoter fragment. Only matches with a Matrix Similarity Score ≥ 0.9 are shown.

^a Anchor corresponds to the center nucleotide position of a binding site; coordinates are from the 365 bp promoter fragment.

^b Strand corresponds to orientation within the gene: +5' \rightarrow 3', -3' \rightarrow 5'.

(Yop51) [30], and the bovine acid phosphatase 1 (Acp1; LMW-PTP) [31]. It is characterized by the presence of consensus catalytic residues, CX₅RS/T, located in the PTP-loop. Our studies that *Synj2*^{DSac1} truncates a significant fraction of the Sac1 homology domain without deleting the catalytic site residues. Whether or not this catalytic site is functional remains to be determined.

The alternate splice variants of *Synj2*^{DSac1} produced by germ cells versus somatic cells may indicate cell-type specific differential expression of splice factors or accessory proteins. This phenomenon could lead to synthesis of germ cell-specific and somatic cell-specific protein isoforms that perform distinct functions. It is revealing that the switch from high to low transcript sizes for *Synj2*^{DSac1} occurs at the tail-end of prophase I of meiosis as seen in Fig. 3, possibly reflecting the need to transition from meiosis to a transcriptionally arrested spermatid. The absence of detectable *Synj2* and any of its isoforms in mouse testis by Western blot was unexpected, although its absence may be due to alternative splicing in the 3' region of the gene resulting in a loss of the epitope, consistent with the large transcript variation observed at this locus.

Acknowledgments

I thank Pietro De Camilli for the anti-Synj2 antibody, Chris Smith for DNA sequencing and Andrew Christie for insightful comments on the manuscript. I also thank Jeffrey Calhoun, William Frels, Nataliya Ilyashenko and Ashley Wolf for technical assistance. This work was supported by a grant from the INBRE program of the National Institutes of Health (P20 RR016463) and from North Carolina State University (NC07313).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bbrc.2013.09.115>.

References

- [1] S. Guo et al., SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases, *J. Biol. Chem.* 274 (1999) 12990–12995.
- [2] P.S. McPherson et al., A presynaptic inositol-5-phosphatase, *Nature* 379 (1996) 353–357.
- [3] Y. Nemoto et al., Synaptojanin 2, a novel synaptojanin isoform with a distinct targeting domain and expression pattern, *J. Biol. Chem.* 272 (1997) 30817–30821.
- [4] Y. Nemoto et al., Identification and characterization of a synaptojanin 2 splice isoform predominantly expressed in nerve terminals, *J. Biol. Chem.* 276 (2001) 41133–41142.
- [5] P.S. McPherson et al., P145, a major Grb2-binding protein in brain, is co-localized with dynamin in nerve terminals where it undergoes activity-dependent dephosphorylation, *J. Biol. Chem.* 269 (1994) 30132–30139.
- [6] R. Woscholski, M.D. Waterfield, P.J. Parker, Purification and biochemical characterization of a mammalian phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase, *J. Biol. Chem.* 270 (1995) 31001–31007.
- [7] C. David et al., A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals, *Proc. Natl. Acad. Sci. USA* 93 (1996) 331–335.
- [8] E. de Heuvel et al., Identification of the major synaptojanin-binding proteins in brain, *J. Biol. Chem.* 272 (1997) 8710–8716.
- [9] N. Ringstad, Y. Nemoto, P. De Camilli, The SH3p4/Sh3p8/SH3p13 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain, *Proc. Natl. Acad. Sci. USA* 94 (1997) 8569–8574.
- [10] B. Qualmann et al., Syndapin 1, a synaptic dynamin-binding protein that associates with the neural Wiskott–Aldrich syndrome protein, *Mol. Biol. Cell* 10 (1999) 501–513.
- [11] N. Rusk et al., Synaptojanin 2 functions at an early step of clathrin-mediated endocytosis, *Curr. Biol.* 13 (2003) 659–663.
- [12] L.F. Seet et al., Molecular cloning of multiple isoforms of synaptojanin 2 and assignment of the gene to mouse chromosome 17A2-3.1, *Biochem. Biophys. Res. Commun.* 247 (1998) 116–122.
- [13] M. Khvotchev, T.C. Sudhof, Developmentally regulated alternative splicing in a novel synaptojanin, *J. Biol. Chem.* 273 (1998) 2306–2311.
- [14] Y. Nemoto, P. De Camilli, Recruitment of an alternatively spliced form of synaptojanin 2 to mitochondria by the interaction with the PDZ domain of a mitochondrial outer membrane protein, *EMBO J.* 18 (1999) 2991–3006.
- [15] B.M. Lange, K. Gull, A molecular marker for centriole maturation in the mammalian cell cycle, *J. Cell Biol.* 130 (1995) 919–927.
- [16] J.C. Schimenti, J.L. Reynolds, A. Planchart, Mutations in Serac1 or Synj2 cause proximal t haplotype-mediated male mouse sterility but not transmission ratio distortion, *Proc. Natl. Acad. Sci. USA* 102 (2005) 3342–3347.
- [17] N. Malecz et al., Synaptojanin 2, a novel Rac1 effector that regulates clathrin-mediated endocytosis, *Curr. Biol.* 10 (2000) 1383–1386.
- [18] J. Kawai et al., Functional annotation of a full-length mouse cDNA collection, *Nature* 409 (2001) 685–690.
- [19] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, *Nature* 227 (1970) 680–685.
- [20] H. Towbin, T. Staehelin, J. Gordon, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, *Proc. Natl. Acad. Sci. USA* 76 (1979) 4350–4354.
- [21] U. Dissing, B. Mattiasson, Polyelectrolyte complexes as vehicles for affinity precipitation of proteins, *J. Biotechnol.* 52 (1996) 1–10.

- [22] K. Nocka et al., Molecular bases of dominant negative and loss of function mutations at the murine *c-kit*/white spotting locus: W37, Wv, W41 and W, *EMBO J.* 9 (1990) 1805–1813.
- [23] M. Kozak, Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes, *Proc. Natl. Acad. Sci. USA* 87 (1990) 8301–8305.
- [24] N. Abuladze et al., Structural organization of the human *NBC1* gene: *kNBC1* is transcribed from an alternative promoter in intron 3, *Gene* 251 (2000) 109–122.
- [25] H. Liang, J. Lunec, Characterisation of a novel p53 down-regulated promoter in intron 3 of the human *MDM2* oncogene, *Gene* 361 (2005) 112–118.
- [26] L.R. Rohrschneider et al., The intron 5/6 promoter region of the *shp1* gene regulates expression in stem/progenitor cells of the mouse embryo, *Dev. Biol.* 283 (2005) 503–521.
- [27] S. Yu et al., Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4, *J. Biol. Chem.* 278 (2003) 19597–19602.
- [28] J.W. Fickett, A.G. Hatzigeorgiou, Eukaryotic promoter recognition, *Genome Res.* 7 (1997) 861–878.
- [29] A.E. Cleves, P.J. Novick, V.A. Bankaitis, Mutations in the *SAC1* gene suppress defects in yeast Golgi and yeast actin function, *J. Cell Biol.* 109 (1989) 2939–2950.
- [30] J.A. Stuckey et al., Crystal structure of *Yersinia* protein tyrosine phosphatase at 2.5 Å and the complex with tungstate, *Nature* 370 (1994) 571–575.
- [31] X.D. Su et al., The crystal structure of a low-molecular-weight phosphotyrosine protein phosphatase, *Nature* 370 (1994) 575–578.